All In Biotech

Free tool

FAERS Monitor: Caprelsa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022405 or its brand name (Caprelsa, Vandetanib). Reports on generic versions are filed under their own applications.

Reports

1,815

Serious

1,215

67% of reports

Hospitalization

532

Death reported

164

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea332
  • rash177
  • fatigue176
  • electrocardiogram qt prolonged142
  • hypertension115
  • nausea114
  • acne98
  • disease progression81
  • asthenia79
  • blood pressure increased79
  • dyspnoea77
  • headache74
  • death73
  • decreased appetite65
  • insomnia58

Reports by year received

View as table
YearReports
20072
200817
200921
201020
2011149
2012247
2013119
201471
201578
2016115
201762
201885
201973
2020135
2021150
2022123
2023111
202499
202578
202660

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,344 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
electrocardiogram qt prolongedSignal14245.939.26,183
acneSignal9815.012.41,269
disease progressionSignal817.96.4487
hypertensionSignal1156.35.3512
blood pressure increasedSignal796.04.8326
diarrhoeaSignal3326.05.41,409
rashSignal1774.74.1524
decreased appetiteSignal653.22.6100
fatigueSignal1762.62.3181
insomniaSignal582.52.053
astheniaSignal792.42.067
nausea1141.71.431
dyspnoea771.61.316
headache741.41.17
death731.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.